Remote hearing tests for patients with head and neck cancer receiving chemotherapy or radiation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of remote audiometry in monitoring hearing loss in patients with advanced head and neck squamous cell carcinoma undergoing treatment with cisplatin and/or radiation. The study aims to increase participation in hearing loss monitoring by offering tests closer to home for patients living more than 120 miles away or those with stage IV disease. Patients are randomized into two groups: one receiving standard audiometry at a medical center and the other offered remote testing options. The trial also seeks to assess the incidence of cisplatin-induced hearing loss and identify barriers to participation in monitoring.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients, male or female, aged ≥ 18, able to provide informed consent
* Subjects with pathologically proven HNSCC involving the oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, skin, or paranasal sinuses; patients with unknown primary HNSCC involving the cervical lymph nodes can also be included. Patients can have previously untreated or recurrent/metastatic disease
* Subjects who will be treated with cisplatin chemotherapy and/or radiation. For radiation alone, patients should have tumors near the inner ear, including the nasopharynx, temporal bone, and/or parotid salivary gland
* Life expectancy of more than 3 months, as determined by the investigator

Exclusion Criteria:

* Patients with profound hearing loss in both ears, which precludes an accurate hearing test. This can be determined based on patient report/history or audiogram done before or after informed consent
* Patients who are unable to participate in a hearing test (per the investigator's judgment)

Where it's running

• Emory Midtown University Hospital/Winship Cancer Institute
  Atlanta, Georgia, United States Recruiting

Study contacts

• Principal investigator: Nicole C Schmitt, MD, FACS — Emory University Hospital/Winship Cancer Institute
• Study coordinator: Mo Oyewole
• Email: mosope.desayo.oyewole@emory.edu
• Phone: 4047785351

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining lovastatin and pembrolizumab for advanced head and neck cancer treatment

  This study is testing if combining a cholesterol-lowering drug called lovastatin with an immunotherapy drug called pembrolizumab can help people with advanced head and neck cancer feel better and live longer.

  Recruiting at 2 sites Phase 2 Emory University · Atlanta, Georgia and 1 other locations · NCT06636734

• Autologous tumor membrane vesicle (TMV) vaccine alone or with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma

  This trial tests whether a vaccine made from a patient's own tumor (TMV), given alone or with pembrolizumab, can help people with recurrent or metastatic head and neck squamous cell carcinoma who had tumor tissue banked at surgery.

  Recruiting at 2 sites Phase 1 Emory University · Atlanta, Georgia and 1 other locations · NCT06868433

• Combining cetuximab with pembrolizumab for advanced head and neck cancer

  This study is testing if adding cetuximab to pembrolizumab can help people with advanced head and neck cancer live longer and feel better compared to just using pembrolizumab alone.

  Recruiting at 192 sites Phase 3 National Cancer Institute (NCI) · Little Rock, Arkansas and 201 other locations · NCT06589804

• Cemiplimab with or without CDX-1140 given before surgery for stage III-IV head and neck cancer

  This trial tests whether adding the immune stimulant CDX-1140 to cemiplimab before surgery helps shrink tumors in people with resectable stage III-IV head and neck squamous cell carcinoma.

  Recruiting at 12 sites Phase 2 National Cancer Institute (NCI) · Irvine, California and 11 other locations · NCT06980038

• Combining cabozantinib and nivolumab to treat advanced melanoma and head and neck cancer

  This study is testing a combination of two cancer drugs, cabozantinib and nivolumab, to see if they can help people with advanced melanoma or head and neck cancer while also looking at how to better match treatments to patients based on their tumor characteristics.

  Recruiting at 211 sites Phase 2 National Cancer Institute (NCI) · Phoenix, Arizona and 231 other locations · NCT05136196

• Camonsertib added to precise radiation therapy for recurrent head and neck cancer

  This early-phase study tests whether the cancer drug camonsertib, given with targeted SBRT radiation, is safe and tolerable for people with recurrent or unresectable head and neck squamous cell carcinoma.

  Recruiting at 4 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 3 other locations · NCT07156227

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.